Astrocyte Pharmaceuticals gets $6M to advance novel brain injury therapeutic

With your risk of dementia your doctor should be closely following this. In fact earlier research(April 2023) has these lines:

The study showed compelling benefits for AST-004 treatment slowing stroke lesion growth, preserving at risk penumbra tissue, and substantially reducing the amount of brain tissue lost to the stroke. The research included novel pharmacokinetic/pharmacodynamic (PK/PD) modeling enabling estimates of a recommended human dose.

If your doctor doesn't know about this s/he is incompetent! 

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

Do you prefer your doctor incompetence in this NOT KNOWING? OR NOT DOING?

Astrocyte Pharmaceuticals gets $6M to advance novel brain injury therapeutic 

A Boston-area clinical stage drug discovery and development company announced $6 million in pre-Series B bridge financing to advance a novel cerebroprotectant therapeutic intended to treat a broad range of acute brain injuries.

According to a release from Astrocyte Pharmaceuticals, the financial infusion, which was led by Dreavent Capital in conjunction with the Alzheimer’s Drug Discovery Foundation, is expected to accelerate clinical development of AST-004, which also may show potential for treatment of neurodegenerative conditions such as Alzheimer’s disease.

Astrocyte Pharmaceuticals received $6M in financing to advance AST-004, a novel therapeutic for acute brain injuries. Image: Adobe Stock

“There are millions of patients living with brain injuries worldwide who face limited treatment options for these devastating conditions,” William Korinek, PhD, CEO, Astrocyte Pharmaceuticals, stated in the release. “With this additional funding, we are poised to accelerate the clinical development of AST-004 and move one step closer to proving this novel approach can benefit patients in dire need.”

Astrocyte also revealed in its release that phase 1b clinical safety studies of AST-004 are underway, with plans to launch phase 2 efficacy studies in 2024.

“Finding innovative ways to target inflammation in the brain will play an important role in the future of combination therapy and precision medicine for Alzheimer’s disease,” Howard Fillit, MD, cofounder and chief science officer, Alzheimer’s Drug Discovery Foundation, said in the release. “Astrocyte’s approach using AST-004 holds promise for reducing astrocyte-induced excess inflammation.”